Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection

References

• Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden of disease study 2013. Lancet. 2016;388:1081–1088.
   PubMed Web of Science ®Google Scholar
• Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77–87.
   PubMed Web of Science ®Google Scholar
• Bandiera S, Billie Bian C, Hoshida Y, et al. Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma. Curr Opin Virol. 2016;20:99–105.
   PubMed Web of Science ®Google Scholar
• Incorporated VP. INCIVEKTM (telaprevir) film coated tablets US Prescribing Information. Cambridge: Vertex Pharmaceuticals Incorporated; 2013.
   Google Scholar
• Merck Co Inc. VICTRELIS® (boceprevir) capsules for oral use. U.S Prescribing Information. Whitehouse Station. Revised. September 2013.
   Google Scholar
• González-Grande R, Jiménez-Pérez M, González Arjona C, et al. New approaches in the treatment of hepatitis C. World J Gastroenterol. 2016;22:1421–1432.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA approves Epclusa for treatment of chronic hepatitis C virus infection. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm508915.htm. Accessed october 28, 2016.
   Google Scholar
• Bristol-Myers Squibb Company. DAKLINZA^TM (daclatasvir) tablets, for oral use. Full prescribing information. Revised. April 2016.
   Google Scholar
• Gilead Sciences. HARVONI® (ledipasvir and sofosbuvir) tablets, for oral use. Full prescribing information. Revised. June 2016.
   Google Scholar
• AbbVie Ltd. VIEKIRA PAK (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), co-packaged for oral use. Full prescribing information. Revised. December 2014.
   Google Scholar
• Merck Co Inc. ZEPATIER^TM (elbasvir and grazoprevir) tablets, for oral use. Full prescribing information. Revised. January 2016.
   Google Scholar
• Gilead Sciences Inc. Epclusa ® (sofosbuvir and velpatasvir) tablets, for oral use: US prescribing information. 2016. http://www.fda.gov. Accessed 10 Nov 2016.
   Google Scholar
• Gilead Sciences. Sovaldi ® (sofosbuvir) tablets for oral use. Full prescribing information. Revised. August 2015.
   Google Scholar
• Janssen-Cilag. OLYSIO ® (simeprevir) capsules, for oral use. Full prescribing information. Revised. December 2013.
   Google Scholar
• Asselah T. Sofosbuvir for the treatment of hepatitis C virus. Expert Opin Pharmacother. 2014;15:121–130.
   PubMed Web of Science ®Google Scholar
• Fung A, Jin Z, Dyatkina N, et al. Efficiency of incorporation and chain termination determines the inhibition potency of 2ʹ-modified nucleotide analogs against hepatitis C virus polymerase. Antimicrob Agents Chemother. 2014 Jul;58(7):3636–3645.
   PubMed Web of Science ®Google Scholar
• Gilead Sciences International Ltd. Epclusav 400/100 mg filmcoated tablets: EU summary of product characteristics. 2016. http://www.ema.europa.eu. Accessed 10 Nov 2016.
   Google Scholar
• Greig SL. Sofosbuvir/Velpatasvir: A review in chronic Hepatitis C. Drugs. 2016;76:1567–1578.
   PubMed Web of Science ®Google Scholar
• German P, Pang P, Yang C, et al. Healthy volunteer first in human evaluation of GS-5816, a novel second generation broad-genotypic NS5A inhibitor with potential for once-daily dosing [abstract 1195]. J Hepatol. 2013;58(suppl):S486.
   Google Scholar
• Lawitz E, Freilich B, Link J, et al. A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1–4 hepatitis C virus. J Viral Hepat. 2015;22:1011–1019.
   PubMed Web of Science ®Google Scholar
• Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015 Dec 31;373(27):2599–2607.
   PubMed Web of Science ®Google Scholar
• Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373:2608–2617.
   PubMed Web of Science ®Google Scholar
• Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618–2628.
   PubMed Web of Science ®Google Scholar
• Wyles D, Brau N, Kottilil S, et al. Sofosbuvir/velpatasvir for 12 weeks in patients coinfected with HCV and HIV-1: the ASTRAL-5 Study. Presented at the 51st Annual Meeting of the European Association for the Study of the Liver, Barcelona, April 13-17, 2016. Abstract PS104.
   Google Scholar
• Kirby BJ, Symonds WT, Kearney BP, et al. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet. 2015;54:677–690.
   PubMed Web of Science ®Google Scholar
• Mogalian E, Osinusi A, Shen G, et al. Effect of food and acid reducing agents on the relative bioavailability and pharmacokinetics of sofosbuvir/velpatasvir fixed-dose combination tablet. Clin Pharm Ther. 2016;99(suppl):S43–S44.
   Google Scholar
• Keating GM. Sofosbuvir: a review of its use in patients with chronic hepatitis C. Drugs. 2014;74(10):1127–1146.
   PubMed Web of Science ®Google Scholar
• Mariño Z, Van Bömmel F, Forns X, et al. New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C. Gut. 2014;63(2):207–215.
   PubMed Web of Science ®Google Scholar
• Chahine EB, Sucher AJ, Hemstreet BA. Sofosbuvir/velpatasvir: the first pangenotypic direct-acting antiviral combination for hepatitis C. Ann Pharmacother. 2016 Sep 8 pii: 1060028016668897. Epub ahead of print.
   Google Scholar
• Rose L, Bias TE, Mathias CB, et al. Sofosbuvir: a nucleotide NS5B inhibitor for the treatment of chronic hepatitis C infection. Annals of Pharmacotherapy. 2014;48:1019–1029.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Rodriguez-Torres M, Cornpropst MT, et al. The effect of hepatic impairment on the pharmacokinetics and antiviral activity of PSI-7977 in hepatitis C infected subjects treated for seven days [abstract 1130]. J Hepatol. 2012;56(suppl 2):S445–S446.
   Web of Science ®Google Scholar
• Smolders EJ, De Kanter CT, Van Hoek B, et al. Pharmacokinetics, efficacy, and safety of hepatitis c virus drugs in patients with liver and/or renal impairment. Drug Saf. 2016 Jul;39(7):589–611.
   PubMed Web of Science ®Google Scholar
• Herbst DA Jr, Reddy KR. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs. 2013;22:527–536.
   PubMed Web of Science ®Google Scholar
• Stedman C. Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential. Ther Adv Gastroenterol. 2014;7:131–140.
   PubMed Web of Science ®Google Scholar
• Cornpropst MT, Denning JM, Clemons D, et al. The effect of renal impairment and end stage renal disease on the single dose pharmacokinetics of PSI-7977 [abstract no. 1101]. J Hepatol. 2012;56(suppl1):S433.
   PubMed Web of Science ®Google Scholar
• Everson GT, Towner WJ, Davis MN, et al. Sofosbuvir with Velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis c virus infection: a randomized trial. Ann Intern Med. 2015;163:818–826.
   PubMed Web of Science ®Google Scholar
• Pianko S, Flamm SL, Shiffman ML, et al. Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis c virus infection: a randomized trial. Ann Intern Med. 2015;163:809–817.
   PubMed Web of Science ®Google Scholar
• Renet S, Chaumais MC, Antonini T, et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology. 2015;149:1378–1380.
   PubMed Web of Science ®Google Scholar
• Back DJ, Burger DM. Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned. Gastroenterology. 2015;149:1315–1317.
   PubMed Web of Science ®Google Scholar
• FDA. FDA Drug Safety Communication: FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in combination with another direct acting antiviral drug, 2015; http://www.fda.gov/Drugs/DrugSafety/ucm439484.htm Accessed 10 november 2016.
   Google Scholar
• Mogalian E, German P, Kearney BP, et al. Use of multiple probes to assess transporter- and cytochrome P450-mediated drug-drug interaction potential of the pangenotypic HCV NS5A inhibitor velpatasvir. Clin Pharmacokinet. 2016;55:605–613.
   PubMed Web of Science ®Google Scholar
• Mogalian E, German P, Brainard DM, et al. Lack of a clinicallysignificant drug-drug interaction between sofosbuvir and GS-5816 in healthy volunteers. Hepatology. 2015;58:431A.
   Web of Science ®Google Scholar
• American Association for the Study of Liver Diseases and Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. 2016. http://www.hcvguidelines.org. Accessed 10 Nov 2016.
   Google Scholar
• European Association for the Study of the Liver. EASL recommendations of treatment of hepatitis C 2016. http://www.easl.eu/medias/cpg/HCV2016/Summary.pdf. Accessed 10 Nov 2016.
   Google Scholar
• Asociación Española para el estudio del Hígado and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Guías AEEH/SEIMC de manejo de la hepatitis C 2016. https://www.seimc.org/contenidos/documentoscientificos/guiasclinicas/seimc-clinicasclinicas-2016-Manejo_HepatitisC.pdf. Accessed 10 Nov 2016.
   Google Scholar
• Ampuero J, Romero-Gómez M, Reddy KR. Review article: HCV genotype 3 —the new treatment challenge. Aliment Pharmacol Ther. 2014;39:686–698.
   PubMed Web of Science ®Google Scholar
• Blanco JR, Rivero-Juarez A. HCV genotype 3: a wolf in sheep’s clothing. Expert Rev Anti Infect Ther. 2016;14(2):149–152.
   PubMed Web of Science ®Google Scholar